Duvelisib (Copiktra) — Coverage Criteria and Prior Authorization
Defines medical necessity criteria, dosing limits, and prior authorization requirements for duvelisib (Copiktra) for CLL/SLL and certain T-cell lymphomas for Centene lines of business.
For CLL/SLL, prior therapy requirement revised from at least one therapy to prior therapy with a BTK inhibitor and venetoclax-based regimens per NCCN and PI.
Dosing requirements updated to reflect modified dosing recommendations for co-administration with a moderate CYP3A4 inducer.
Off-label indications for follicular lymphoma (FL) and marginal zone lymphoma (MZL) were removed because they are no longer supported by NCCN.
Off-label criteria for T-cell lymphomas supported by NCCN were added, including requirement for use as a single agent.
Coverage Criteria
Initial Therapy
Covered when ALL of the following are met:
See Appendix B for examples of prior therapies and Appendix D for CYP3A4 inducers.
Initial Therapy - T‑cell lymphomas (off‑label)
Covered when ALL of the following are met for specified T‑cell lymphoma subtypes:
Off‑label coverage pathway requiring supporting evidence; NCCN‑supported indications only.
Continuation Therapy
Continued coverage when ALL of the following are met:
Approval durations differ by line of business.
Revised CLL/SLL coverage requirements
Noted coverage stance and specific clinical prerequisites per updated policy narrative
Prior therapy requirement revised from 'at least one therapy' to specific agents per NCCN and PI; see policy revision history for details.
Off-label T-cell lymphoma
Off‑label T‑cell lymphoma (NCCN‑supported)
Off‑label but NCCN‑supported; criterion for single‑agent use added in 4Q2023.
Requests for non‑FDA approved indications that are not specifically addressed by this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (for example, CP CPA.09 for commercial lines and HIM.PA.154 for health insurance marketplace).
Off‑label coverage criteria previously allowing use for follicular lymphoma (FL) and marginal zone lymphoma (MZL) have been removed because these indications are no longer supported by NCCN guidance; requests for FL or MZL therefore do not meet the off‑label coverage pathway under this policy.
Copiktra (duvelisib) is not indicated or recommended for initial or second‑line treatment of CLL/SLL because clinical data demonstrate an increased risk of treatment‑related mortality; coverage is limited to later‑line use per the FDA‑labeled limitation of use.
Use of duvelisib for follicular lymphoma (FL) and marginal zone lymphoma (MZL) is considered no longer supported by NCCN and therefore is not covered under the off‑label criteria in this policy.
Covered Regimens and Dosing
| Regimen | Details | Coverage Status |
|---|---|---|
| Standard dosing | ||
| 25 mg PO twice daily (may reduce to 15 mg PO twice daily for adverse reactions); treatment cycles per prescribing information. | ||
| Dose limits |
| Regimen | Requirements | Coverage Status |
|---|---|---|
| Duvelisib as single agent | ||
| Use as a single agent per NCCN guidance for supported T‑cell lymphoma subtypes; prescriber must submit supporting evidence per policy off‑label requirements. | ||
| Covered with criteria |
Coding and Dose Limits
Provider Actions and Prior Authorization
Prior Authorization and Required Criteria
Prior authorization is required. Provider must demonstrate that all medical necessity criteria are met for the requested use.
- Prior authorization required for Copiktra (duvelisib) requests for CLL/SLL.
- Prescribed by or in consultation with an oncologist or hematologist.
Prior Authorization Clinical Prerequisites
For CLL/SLL, prior therapy prerequisites must be documented. Coverage requires the disease to be relapsed or refractory after prior therapy with both a BTK inhibitor and a venetoclax-based regimen (see Appendix B for examples). Requests must show prior use of these specific therapies before approval.
- Prior therapy must include a BTK inhibitor (e.g., acalabrutinib, ibrutinib, zanubrutinib, pirtobrutinib).
- Prior therapy must include a venetoclax-based regimen (e.g., venetoclax ± anti-CD20 antibody such as obinutuzumab).
Off‑label Indication Removal
Use of duvelisib for follicular lymphoma (FL) and marginal zone lymphoma (MZL) is no longer supported by NCCN and the off‑label criteria for these indications have been removed. Requests for these indications risk denial.
- Off‑label FL and MZL indications removed per latest NCCN updates.
- Off‑label requests not supported by NCCN require sufficient documentation per off‑label use policies.
Supportive Documentation Required
Provider must submit supporting documentation with the prior authorization request. Acceptable documentation includes office chart notes, laboratory results, and other clinical information that confirm diagnosis, prior therapies, and rationale for use.
- Include office chart notes documenting relapsed/refractory status and prior treatment history.
- Include lab results and any relevant imaging or pathology reports as applicable.
Prior Therapy Documentation
Documentation must specifically support the prior therapy history required for CLL/SLL. The submission should clearly show prior treatment with a BTK inhibitor and a venetoclax‑based regimen, including dates, doses, and reasons for discontinuation (e.g., progression or intolerance).
- List prior agents, start/stop dates, dosing, and response.
- Provide evidence (clinic notes, progression dates) that therapy was ineffective or not tolerated.
Prior Therapy Requirements
Coverage requires prior relapsed/refractory status after the specified prior therapies and that duvelisib is prescribed as a single agent for CLL/SLL per updated policy. Dosing must follow FDA label or NCCN recommendations; generic oral oncology redirection applies where appropriate.
- Duvelisib must be used as a single agent for CLL/SLL.
- Dose limits: typically 50 mg per day; do not exceed 2 capsules per day; adjustments apply when co‑administered with moderate CYP3A4 inducers per Appendix D and PI.
- Generic duvelisib redirection applicable when available unless contraindicated.
Line-of-Therapy Definitions
second-line_or_later
FDA indication requires prior ≥2 therapies; policy limits initial/second‑line use per PI.
salvage
Defines allowable salvage settings for off‑label T‑cell lymphoma coverage.
second-line
Change documented in policy revision history.
Definitions and Safety
Background
Duvelisib (Copiktra) is an oral phosphoinositide 3‑kinase inhibitor indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. The product carries boxed warnings for treatment‑related mortality and serious toxicities including infections, diarrhea/colitis, cutaneous reactions, and pneumonitis. Standard dosing for CLL/SLL is 25 mg PO twice daily (dose reductions to 15 mg PO twice daily may be used for adverse reactions); dose limits for this policy are 50 mg per day (or up to 80 mg per day when co‑administered with a moderate CYP3A4 inducer), and dosing adjustments and resumption instructions follow the prescribing information. Prior authorization is required and coverage is restricted to the labeled relapsed/refractory population and to off‑label T‑cell lymphoma indications only when supported by NCCN and used as a single agent per NCCN guidance.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.